X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Takeda selected for the sixth consecutive year for Dow Jones Sustainability Asia Pacific Index

Yuvraj_pawp by Yuvraj_pawp
5th October 2015
in Facilities & Operation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Takeda Pharmaceutical Company Ltd. (“Takeda”, TSE: 4502) has been selected for the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific) for the sixth consecutive year. Takeda has been included in the DJSI Asia Pacific since 2010 for its sustainability performance.

DJSI Asia Pacific is part of the Dow Jones Sustainability Indexes (DJSI). It is designed for companies in the developed Asia Pacific markets and comprises 145 companies, including 62 Japanese companies, that are leading the way in terms of sustainability among the 600 companies in the region. For inclusion in the DJSI Asia Pacific, Dow Jones assesses companies based on questionnaire responses, annual reports from each company and publicly available company information.

For Takeda, CSR is rooted in putting the patient in the center and operating a pharmaceutical business that creates outstanding products. The company also strives to maintain and improve sound business processes, and to engage in activities to promote a sustainable society as a good corporate citizen. In doing so, it is implementing a model of value creation and preservation through CSR. This will help Takeda to build trust with society, reinforce its reputation, and further develop the pharmaceutical business.

Takeda promotes CSR activities in line with internationally recognized guidelines, such as the United Nations Global Compact’s 10 principles. The company is also included in the FTSE4Good Global Index by the FTSE Group and the Morningstar Socially Responsible Investment Index (MS-SRI) compiled by Morningstar Japan K.K.

DJSI is one of the world’s foremost indices for Socially Responsible Investment. It assesses and selects leading sustainability-driven companies based on economic, environmental, and social criteria. Thus it serves as an important indicator for investors considering corporate social responsibility (CSR) performance. It is provided by S&P Dow Jones Indices LLC of the United States.

Previous Post

Gencia and Takeda Team to Discover and Develop Novel Class of Mitochondrial Therapeutics

Next Post

Takeda Submits a New Drug Application for the Fixed-Dose Combination of Nesina® and Metformin Hydrochloride for the Treatment of Type 2 Diabetes in Japan

Related Posts

API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
API Manufacturing Facility
Americas

Lilly to Build $6.5B API Manufacturing Facility in Houston

25th September 2025
Merck and Siemens
Drug Development

Merck and Siemens to Accelerate AI Driven Drug Development

24th September 2025
Scottish Pharma Sector
Europe

ABPI Launches Manifesto to Advance Scottish Pharma Sector

23rd September 2025
Automating Experimental Design with Generative AI in Pharma
Facilities & Operation

Automating Experimental Design with Generative AI in Pharma

20th September 2025
Next Post

Takeda Submits a New Drug Application for the Fixed-Dose Combination of Nesina® and Metformin Hydrochloride for the Treatment of Type 2 Diabetes in Japan

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In